Analyst Price Targets — DTIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 6:57 pm | Maury Raycroft | Jefferies | $19.00 | $5.67 | StreetInsider | Precision BioSciences Inc. (DTIL) PT Lowered to $19 at Jefferies, but 'near-term setup is attractive' |
| April 1, 2024 7:19 am | Justin Zelin | BTIG | $30.00 | $13.56 | TheFly | Precision BioSciences price target raised to $30 from $2 at BTIG |
| November 10, 2022 10:11 am | — | Goldman Sachs | $1.00 | $1.38 | Benzinga | Goldman Sachs Maintains Neutral on Precision BioSciences, Lowers Price Target to $1 |
Latest News for DTIL
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the first quarter 2026 and provide a business update on May 5, 2026. About Precision BioSciences, Inc. Precision BioSciences,…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene editing…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on April 20, 2026, the Compensation Committee of Precision's Board of Directors approved the grant of an inducement award of 7,094 restricted stock units (“RSUs”)…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DTIL.
U.S. House Trading
No House trades found for DTIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.